Close Menu

Looking Into It

A second death in a trial of Novartis' gene therapy, Zolgensma, for type 1 spinal muscular atrophy is under investigation, Reuters reports. Type 1 SMA leads to paralysis and breathing trouble.

Reuters adds that the firm recently reported positive interim trial results and filed for US Food and Drug Administration approval based on a trial of 15 babies given Zolgensma. Reuters notes that a decision is expected within weeks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.